Erratum: Discovery of LY2457546: A multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model (Invest New Drugs DOI: 10.1007/s10637-011-9640-6);Discovery of LY2457546: A multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model

Investigational New Drugs

Volumn 30, Issue 3, 2012, Pages 936-949

  Burkholder, Timothy P ^a   Clayton, Joshua R ^a   Rempala, Mark E ^a   Henry, James R ^a   Knobeloch, John M ^a   Mendel, David ^a   McLean, Johnathan A ^a   Hao, Yan ^a   Barda, David A ^a   Considine, Eileen L ^a   Uhlik, Mark T ^a   Chen, Yuefeng ^a   Ma, Liandong ^a   Bloem, Laura J ^a   Akunda, Jacqueline K ^a   McCann, Denis J ^a   Sanchez Felix, Manuel ^a   Clawson, David K ^a   Lahn, Michael M ^a   Starling, James J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

AML; In vivo target inhibition; LY2457546; Multikinase inhibitor; Sunitinib; Xenograft efficacy

Indexed keywords

ANTINEOPLASTIC AGENT; LY 2457546; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; CANCER REGRESSION; CHONDRODYSPLASIA; COLON CANCER; CONTROLLED STUDY; DEPIGMENTATION; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FEMALE; HAIR DISCOLORATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RAT; TOXICITY TESTING; TUMOR XENOGRAFT;

EID: 84864353935     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9684-7     Document Type: Erratum

References (24)

1. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011-1027 (Pubitemid 46202320)
2. Takahashi H, Shibuya M (2005) The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci 109:227-241 (Pubitemid 41337127)
3. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337 (Pubitemid 36109749)
4. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109 (Pubitemid 39331023)
5. Casanovas O, Hicklin DJ, Bergers G, Hanahan D (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signalling in late-stage pancreatic islet tumors. Cancer Cell 8:299-309 (Pubitemid 41443415)
6. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J (2000) Vascular-specific growth factors and blood vessel formation. Nature 407:242-248
7. Barda DA, Burkholder TP, Clayton JR, Hao Y, Henry JR, Knobeloch JM, McLean JA, Mendel D, Rempala ME, Wang ZQ, Yip YY, Zhong B (2010) U.S. Patent 7 666 879
8. Okram B, Nagle A, Adrian FJ, Lee C, Ren P, Wang X, Sim T, Xie Y Wang X, Xia G, Spraggon G, Warmuth M, Liu Y, Gray N (2006) A general strategy for creating "inactive-conformation" Abl inhibitors. Chem Biol 13:779-786 (Pubitemid 44109805)
9. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J (2000) Sructural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289:1938-1942
10. Manley PW, Bold G, Bruggen J, Fendrich G, Furet P, Mestan J, Schnell C, Stolz B, Meyer T, Meyhack B, Stark W, Strauss A, Wood J (2004) Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment ofangiogenesis. Biochim Biophys Acta 1697:17-27 (Pubitemid 38326758)
11. Sammond DM, Nailor KE, Veal JM, Nolte RT, Wang L, Knick VB, Rudolph SK, Truesdale AT, Nartey EN, Stafford JA, Kumar R, Cheung M (2005) Discovery of a novel and potent series of dianilinopyrimidineurea and urea isostere inhibitors of VEGFR2 tyrosine kinase. Bioorg Med Chem Lett 15:3519-3523 (Pubitemid 40942046)
12. Jung FH, Pasquet G, Lambert-van der Brempt C, Lohman JM, Warin N, Renaud F, Germain H, De Savi C, Roberts N, Johnson T, Dousson C, Hill GB, Mortlock AA, Heron N, Wilkinson RW, Wedge SR, Heaton SP, Odedra R, Keen NJ, Green S, Brown E, Thompson K, Brightwell S (2006) Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors. J Med Chem 49:955-970 (Pubitemid 43221644)
13. Huss KL, Blonigen PE, Campbell RM (2007) Development of a Transcreener kinase assay for protein kinase A and demonstration of concordance of data with a filter-binding assay format J Biomol Screen 12:578-584 (Pubitemid 46871828)
14. Wang X, Mader MM, Toth JE, Yu X, Jin N, Campbell RM, Smallwood JE, Christe ME, Chatterjee A, Goodson T Jr, Vlahos CJ, Matter WF, Bloem LJ (2005) Complete inhibition of anisomycin and UV radiation but not cytokine induced JNK and p38 activation by an aryl-substituted dihydropyrrolopyrazole quinoline and mixed lineage kinase 7 small interfering RNA. J Biol Chem 280:19298-19305 (Pubitemid 41379637)
15. Hasumi Y, Babaa M, Ajimab R, Hasumi H, Valeraa VA, Kleina ME, Hainesc DC, Merinod MJ, Honga S-B, Yamaguchib TP, Schmidt LS, Linehana WM (2009) Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 andmTORC2 PNAS, 106: 18722-18727
16. Chen Y Wei T, Yan L, Lawrence L, Qian H-R, Burkholder TP, Starling JJ, Yingling JM, Shou J (2008) Developing and applying a gene functional association network for anti-angiogenic kinase inhibitor activity assessment in an angiogenesis co-culture model. BMC Genomics 9:264
17. Abu-Ehuler FM, Goodeve AC, Wilson GA, Gari MA, Peake IR, Rees DC, Vandenberghe EA, Winship PR, Reilly JT (2000) FLT3 internal tandem duplication mutations in adult acute myeloid leukemia define a high-risk group. Br J Haematol 111:190-195
18. Rombouts WJ, Blokland I, Lowenberg B, Ploemacher RE (2000) (2000) Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia 14(4):675-683 (Pubitemid 30195459)
19. Meshinchi S, Woods WG, Stirewalt DL, Sweetser DA, Buckley JD, Tjoa TK, Bernstein ID, Radich JP (2001) Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 97:89-94 (Pubitemid 32061246)
20. Obermann EC, Arber C, Jotterand M, Tichelli A, Hirschmann P, Tzankov A (2010) Expression ofpSTAT5 predicts FLT3 internal tandem duplications in acute myeloid leukemia. Ann Hematol 89:663-669
21. Hall AP, Westwood FR, Wadsworth PF (2006) Review of the effects of anti-angiogenic compounds on the epiphyseal growth plate. Toxicol Pathol 34(2):131-4
22. Moss KG, Toner GC, Cherrington JM, Mendel DB, Laird AD (2003) Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans. J Pharmacol Exp Ther 307 (2):476-80 (Pubitemid 37310659)
23. Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, Wechsler J, Lhomme C, Escudier B, Boige V, Armand JP, Le Chevalier T(2005) Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6(7):491-500 (Pubitemid 40903630)
24. Robert C, Spatz A, Faivre S, Armand JP, Raymond E (2003) Tyrosine kinase inhibition and grey hair. Lancet 361(9362):1056 (Pubitemid 36351380)